New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareEloralintide vs DSIP

Eloralintide vs DSIP

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Eloralintide
Sleep OptimizationCognitive Enhancement
DSIP
Summary
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
Half-Life
~7 days (estimated, long-acting design)
~30–60 minutes; however downstream sleep effects last 4–6 hours
Admin Route
SubQ
SubQ, IV, Intranasal
Research
Typical Dose
Under investigation in Phase 1/2 trials
100–400 mcg
Frequency
Once weekly
Once nightly
Key Benefits
  • Once-weekly dosing (vs multiple daily injections for pramlintide)
  • Appetite suppression via central amylin receptor activation
  • Reduction in post-meal glucagon secretion
  • Complementary mechanism to GLP-1 agonists for combination therapy
  • Slows gastric emptying for prolonged satiety
  • Potential additive weight loss when combined with GLP-1 agents
  • Induces and deepens delta-wave (slow-wave) sleep
  • Reduces cortisol and normalizes HPA axis
  • Improves sleep quality in insomnia patients
  • Anti-stress and anxiolytic effects
  • May improve opiate/alcohol withdrawal symptoms
  • Analgesic properties through opioid modulation
  • Antioxidant and neuroprotective effects
Side Effects
  • Nausea
  • Vomiting
  • Decreased appetite
  • Injection site reactions
  • +1 more
  • Generally well tolerated
  • Mild grogginess next morning at higher doses
  • Rare: hypotension
  • Potential for altered dream patterns
Stacks With